EndoChoice Holdings Inc. (GI) Rating Reiterated by William Blair
EndoChoice Holdings Inc. (NYSE:GI)‘s stock had its “market perform” rating reiterated by equities research analysts at William Blair in a report issued on Friday.
GI has been the topic of several other research reports. Stifel Nicolaus decreased their price target on shares of EndoChoice Holdings from $10.00 to $7.00 and set a “buy” rating on the stock in a research note on Thursday, August 4th. Zacks Investment Research cut shares of EndoChoice Holdings from a “buy” rating to a “hold” rating in a research note on Wednesday, August 3rd. Finally, JPMorgan Chase & Co. assumed coverage on shares of EndoChoice Holdings in a research note on Wednesday, July 13th. They issued an “overweight” rating on the stock. One investment analyst has rated the stock with a sell rating, three have given a hold rating and one has given a buy rating to the company. EndoChoice Holdings presently has a consensus rating of “Hold” and an average price target of $7.42.
Shares of EndoChoice Holdings (NYSE:GI) opened at 7.98 on Friday. The stock’s market capitalization is $207.86 million. The firm has a 50-day moving average of $4.67 and a 200 day moving average of $4.79. EndoChoice Holdings has a one year low of $3.64 and a one year high of $12.85.
EndoChoice Holdings (NYSE:GI) last announced its quarterly earnings results on Wednesday, August 3rd. The company reported ($0.99) EPS for the quarter, missing the consensus estimate of ($0.52) by $0.47. The company earned $19.30 million during the quarter, compared to analysts’ expectations of $20.67 million. EndoChoice Holdings had a negative return on equity of 62.04% and a negative net margin of 88.94%. The firm’s revenue for the quarter was up 3.8% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($1.01) EPS. On average, equities research analysts predict that EndoChoice Holdings will post ($2.53) EPS for the current year.
Hedge funds have recently made changes to their positions in the stock. State Street Corp boosted its stake in shares of EndoChoice Holdings by 46.7% in the first quarter. State Street Corp now owns 76,915 shares of the company’s stock valued at $402,000 after buying an additional 24,500 shares in the last quarter. Wellington Management Group LLP boosted its stake in shares of EndoChoice Holdings by 3.5% in the first quarter. Wellington Management Group LLP now owns 2,324,664 shares of the company’s stock valued at $12,111,000 after buying an additional 78,016 shares in the last quarter. Renaissance Technologies LLC boosted its stake in shares of EndoChoice Holdings by 96.5% in the first quarter. Renaissance Technologies LLC now owns 114,606 shares of the company’s stock valued at $597,000 after buying an additional 56,297 shares in the last quarter. Iguana Healthcare Management LLC acquired a new stake in shares of EndoChoice Holdings during the first quarter valued at about $580,000. Finally, Emerald Acquisition Ltd. acquired a new stake in shares of EndoChoice Holdings during the second quarter valued at about $215,000. Hedge funds and other institutional investors own 37.71% of the company’s stock.
About EndoChoice Holdings
EndoChoice Holdings, Inc is a medical device company. The Company is focused on designing and commercializing a platform of products and services for gastrointestinal (GI) caregivers. The Company offers a range of products and services that span single-use devices and infection control products, pathology and imaging systems.
Receive News & Stock Ratings for EndoChoice Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EndoChoice Holdings Inc. and related stocks with our FREE daily email newsletter.